Loading...

Agenda

Home
/
Agenda

February 09-10, 2021 | Virtual Event Platform

REGISTER TODAY
Download Brochure
  • Day 1: February 09, 2021
  • Day 2: February 10, 2021
Come visit our virtual lobby and connect with fellow attendees. You can chat, video, and even make a list of the people you want to meet and the knowledge you’re looking to gain through our bespoke 1:1 match-making services.
Jonathan Banchs, Director of Content and Experience, MOMENTUM EVENTS
  • Unify the approach in your company for managing KOL relationships.
  • Embrace basic philosophies of engagement to approach KOL relationships with a consistent and compliant methodology.
  • Discover ways to establish, develop, strengthen and evaluate these valuable connections and collaborations.

    • Jeff Sears, Associate Director, Commercial Communications, ASTELLAS PHARMA
  • Recognize and be able to use the various ways to optimize your encounters with your KOLs
  • Gain a better understanding of the elements that facilitate productive relationships which leads to productive meetings
  • Learn the facets to stakeholder relationship management and engagement
  • Analyze the benefits of KOL engagement and the value it can provide to patients

    • Howard Berkowitz, Respiratory and Immunology Medical Science Liaison, SANOFI GENZYME
  • Finding new ways to get creative with KOL meetings and avoid virtual burnout
  • Working with MSLs and internal colleagues to identify and access thought leaders who were otherwise inaccessible
  • Taking advantage of the virtual opportunity to connect around the world
  • Tips for keeping engaged internally and externally in the virtual world

    • Courtney Zeni, Director, Medical Affairs, SUNOVION PHARMACEUTICALS

    • A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.

  • The importance of digital evolution for medical affairs and how it can drive KOL engagement
  • The impact of digital on your medical strategy moving forward
  • Principles in building a digital engagement plan that drives results for your organization and for the patients

    • Barry Lubarsky, Executive Director, Medical Affairs Strategy, ALKERMES
  • Perspectives from both Medical Affairs Directors and MSLs
  • Adjustments made during and after the pandemic to enhance the communication between KOLs and MSLs
  • Challenges ahead and applying key learnings from 2020
  • The impact Covid has had on the KOL – MSL interaction and ways we can improve moving forward
  • Hear from various perspectives within medical affairs on their approach to challenges faced post Covid-19

    • Moderator:
    Bryan Bischel, Field Director, Hepatology, MALLINCKRODT PHARMACEUTICALS

    Panelists:
    Caroline Ojaimi, Director – Oncology, Medical Affairs, Strategy and Operations, EISAI
    Delinda Bane, Senior Manager, Medical Science Liaison, Medical Affairs, Parenteral Nutrition, FRESENIUS KABI
    Alan Polnariev, Senior Medical Science Liaison, ASTRAZENECA
  • Importance of KOL identification and tiering/profile process
  • Management of thought leader relationships while working with payors and reimbursement
  • Steps to take to identify raising stars
  • How do Commercial and Medical motivate the KOLs

    • Moderator:
    Gabriel Smolarz, Medical Director Obesity, NOVO NORDISK

    Panelists:
    Jacqueline Armani, Regional MSL Lead, ALCON
    Vanessa Jacobsen, Executive Director, Medical Science Liaisons, NEKTAR THERAPEUTICS
    Kelley Dacus, Associate Director Medical Affairs, RECORDATI RARE DISEASES
  • Understand how to leverage digital tools for effective interactions
  • Which capabilities should we prioritize for virtual interactions?
  • Learn how to best engage with HCPs during virtual congresses
  • Discuss if medical booths are of value in virtual congress settings

    • Eddie Power, Vice President, North America Medical Affairs, Hospital Business, PFIZER
  • Discuss unique processes in the rare disease pathway from research to discovery and key learnings for all in medical affairs
  • Identify opportunities for the role of Medical Affairs throughout the lifecycle of a rare disease product, and learn new tools that can be applied to your therapeutic focus
  • Review new innovative tools for education to HCPs and patients applicable throughout all disease categories

    • Merideth Rodgers, Medical Director, REGENERON PHARMACEUTICALS
    A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.

    Come visit our virtual lobby and connect with fellow attendees. You can chat, video and even make a list of the people you want to meet and knowledge you’re looking to gain through our bespoke 1:1 match-making services.

    Jonathan Banchs, Director of Content and Experience, MOMENTUM EVENTS

    Using research and insights from the science of burnout and mental health, Dr. MUIR explores when burn out is likely to occur, how it can be addressed proactively by engaging in activities that enhance meaning in one’s work, and mitigating the risk of inactivity, unaddressed mental illness, and increased meaninglessness on our relentless workflows.

  • Identify burn out, it’s symptoms, and what it looks like in yourselves and others
  • Learn when burn out and mental onus can lead to more serious risks, and the options that exist for help in that context
  • How to use emerging communications technologies, or not use them, to minimize burn out and enhance feelings of connection while making sure productivity blossoms

    • Owen Muir, Founder and Chief Service Officer, BROOKLYN MINDS

  • Analyze the dynamic role medical affairs teams play in the engagement of internal stakeholders, such as medical directors and scientific affairs leaders
  • Better understand KPI’s through analysis of quantitative and qualitative metrics
  • How to measure performance and success within the MSL role
  • Understand new opportunities for the MSL role to better support commercial teams

    • Ashish Dugar, Vice President Global Medical Affairs, SAREPTA THERAPEUTICS
  • Find ways to maintain communication open so all the key players are on the same page
  • Create clear communication ways to include your Thought Leaders as well, make everyone involved to gain better results
  • Include all the stakeholders even the marketing and sales teams in all steps taken in the process of clinical development to bring synergy and positive feedback

    • Kevin Wu, Senior Medical Director, Global Medicines Development Immunotherapy, ASTRAZENECA

    A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.

  • Gain a better understanding of the role effective medical communication plays during these pivotal phases of a drug launch
  • Develop a comprehensive long-term strategy involving both internal and external stakeholders
  • Simple, clear and specific evidence based approach
  • Consistent value proposition during pre- and post-approval/launch

    • Sudeesh Tantry, Vice President, Global Medical Affairs, GLENMARK PHARMACEUTICALS
  • Compliant behavior in the virtual world
  • How compliant interactions look like for discussions, on label and off label
  • Learn how to handle the difference between solicited and unsolicited requests

    • Jacqueline Armani, Regional MSL Lead, ALCON

  • Gene and cell therapies are revolutionizing patient care, potentially leading to cures in previously untreatable rare and inherited diseases
  • MSLs educating and discussing these therapies with healthcare providers require a solid background in molecular and cellular biology beyond their standard medical knowledge

    • Oscar Segurado, Chief Medical Officer, ASC THERAPEUTICS
  • Define clear objectives for the meeting and select attendees accordingly
  • Choose advisors who will help facilitate the conversation and avoid inviting thought leaders that can have a negative impact on the overall meeting
  • Recognize the importance of following up after an advisory board
  • Provide examples of successful and less successful implementation

    • Kathleen Guindon, Senior Director MSL Team, QED THERAPEUTICS

    • A safe space to talk candidly through your challenges, new tools/tactics. Dedicated VIDEO Q&A time, not only with the speakers but with your industry peers. This is not a live chat or faceless group. This is an opportunity to have an engaged conversation with your industry counterparts and conference speakers.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Privacy Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close